Adamis Pharmaceuticals Seeks Strategic Options, Including Sale
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has initiated a process to explore a range of strategic and financing alternatives. The move follows the recently…
US Supreme Court Turns Away Biogen’s Last Effort To Reinstate Tecfidera Patent
The U.S. Supreme Court decided not to hear the case related to reinstating the patent of Biogen Inc's (NASDAQ: BIIB) blockbuster drug Tecfidera.
Aura Biosciences Details Interim Data From Mid-Stage Study Of Ocular Oncology Drug
Aura Biosciences Inc (NASDAQ:AURA) detailed interim data from its ongoing Phase 2 trial of an eye cancer drug, elzupacap sarotalocan (AU‑011).…
Venus Concept Taps Endo’s Former CEO As New Chief Executive, Withdraws FY22 Guidance
Venus Concept Inc (NASDAQ:VERO) appointed Rajiv De Silva as the company’s CEO and board member, effective October 2. The company…
Clovis Oncology’s Rubraca Hits Primary Goal In Prostate Cancer Settings
Clovis Oncology Inc (NASDAQ:CLVS) announced topline data from the Phase 3 TRITON3 trial, demonstrating that Rubraca monotherapy treatment significantly improved radiographic…
BioCardia’s Heart Failure Cell Therapy Shows 100% Survival At Two Years
BioCardia Inc (NASDAQ:BCDA) announced data from its CardiAMP Cell Therapy for Heart Failure pivotal trial. “The two-year outcomes for patients with…
Investigator Says Apellis’ Lead Product Shows ‘First Direct Evidence Of Slowing Geographic Atrophy Lesion Growth’
Apellis Pharmaceuticals Inc (NASDAQ:APLS) announced new data from the 24-month Phase 3 OAKS study of pegcetacoplan for geographic atrophy (GA) secondary…
RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5
RedHill Biopharma Ltd (NASDAQ:RDHL) announced study results showing in vitro efficacy against the currently dominant omicron COVID-19 sub-variant BA.5, by both…
Why Are LogicBio Therapeutics Shares Skyrocketing Today?
AstraZeneca Plc’s (NASDAQ:AZN) subsidiary, Alexion, has agreed to acquire LogicBio Therapeutics Inc (NASDAQ:LOGC) for $2.07 per share. Both boards have unanimously approved…